Karyopharm Therapeutics Inc (KPTI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $394,660
Last updated: Nov 10, 2026 at 7:59 PM ET
Karyopharm Therapeutics Inc (KPTI) Competitors
The companies most similar to Karyopharm Therapeutics are CERo Therapeutics Holdings, Inc. Common Stock (CERO), CDT Equity (CDT) and Kairos Pharma (KAPA). By market cap, Karyopharm Therapeutics ranks 11th of the 13 companies on this page; Curis (CRIS) is the largest at $2.97M.
Peer Comparison
KPTI's ROIC of 64.5% is above the peer median of -187.9%, and its revenue growth of -11.9% is above the median of -19.2%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Karyopharm Therapeutics (KPTI) | $394660 | N/A | N/A | -153.3% | 64.5% | -11.9% | 0.00% |
| CERo Therapeutics Holdings, Inc. Common Stock (CERO) | $358150 | N/A | N/A | 0.0% | 68.9% | 0.0% | 0.00% |
| CDT Equity Inc. (CDT) | $407550 | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Kairos Pharma, Ltd. (KAPA) | $1.54M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Scisparc Ltd (SPRC) | $869840 | N/A | N/A | 0.0% | N/A | -38.4% | 0.00% |
| Matinas BioPharma Holdings Inc (MTNB) | $881570 | 0.9x | N/A | 0.0% | -187.9% | -100.0% | 0.00% |
| Kala Pharmaceuticals Inc (KALA) | $89480 | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Virax Biolabs Group Limited Ordinary Shares (VRAX) | $823940 | N/A | 14.3x | 0.0% | N/A | 685.0% | 0.00% |
| Oragenics Inc (OGEN) | $906900 | N/A | N/A | 0.0% | -656.1% | -91.3% | 0.00% |
| GeoVax Labs Inc (GOVX) | $928290 | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Scinai Immunotherapeutics Ltd (SCNI) | $1.05M | N/A | N/A | -80.1% | N/A | 572.0% | 0.00% |
| Genprex Inc (GNPX) | $1.71M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Curis Inc (CRIS) | $2.97M | N/A | 1.6x | 0.0% | N/A | -66.0% | 0.00% |
| Peer median | $894235 | 0.9x | 8.0x | 0.0% | -187.9% | -19.2% | 0.00% |
Similar Companies
These are the 12 companies most similar to Karyopharm Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| CERo Therapeutics Holdings, Inc. Common Stock (CERO) | CERo Therapeutics Holdings, Inc. is a biopharmaceutical company dedicated to advancing innovative therapies for patients with serious diseases. | |
| CDT Equity Inc. (CDT) | Conduit Pharmaceuticals Inc. (CDT) is a clinical-stage biopharmaceutical company focused on creating innovative therapies for oncology and rare diseases... | CDT competitors |
| Kairos Pharma, Ltd. (KAPA) | Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. | KAPA competitors |
| Scisparc Ltd (SPRC) | SciSparc Ltd., a specialized clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. | |
| Matinas BioPharma Holdings Inc (MTNB) | Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery and development of several candidate products. | MTNB competitors |
| Kala Pharmaceuticals Inc (KALA) | Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery... | KALA competitors |
| Virax Biolabs Group Limited Ordinary Shares (VRAX) | Virax Biolabs Group Limited, a biotechnology company, sells, distributes and markets diagnostic test kits and medical technology products and PPE... | |
| Oragenics Inc (OGEN) | Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company is headquartered in Tampa, Florida. | OGEN competitors |
| GeoVax Labs Inc (GOVX) | GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using a modified... | GOVX competitors |
| Scinai Immunotherapeutics Ltd (SCNI) | Scinai Immunotherapeutics Ltd is an innovative biotechnology company focused on developing cutting-edge immunotherapy solutions for cancer and autoimmune... | SCNI competitors |
| Genprex Inc (GNPX) | Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. | GNPX competitors |
| Curis Inc (CRIS) | Curis, Inc., a biotechnology company, is dedicated to the discovery and development of drug candidates for the treatment of human cancers in the United States. | CRIS competitors |
Frequently Asked Questions About KPTI
Who are Karyopharm Therapeutics' main competitors?
The companies most similar to Karyopharm Therapeutics include CERo Therapeutics Holdings, Inc. Common Stock (CERO), CDT Equity (CDT), Kairos Pharma (KAPA), Scisparc (SPRC) and Matinas BioPharma Holdings (MTNB), listed from the closest match.
Who is Karyopharm Therapeutics' biggest competitor?
Curis (CRIS) is the largest of the similar companies at $2.97M; CERo Therapeutics Holdings, Inc. Common Stock (CERO) is the closest match by business profile, size, sector and industry.
How does KPTI stock compare with its competitors?
KPTI's net margin is -153.3% against a peer median of 0.0%.
Which of Karyopharm Therapeutics' competitors pays a higher dividend?
Karyopharm Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Karyopharm Therapeutics bigger than its competitors?
No. Karyopharm Therapeutics is 11th by market cap among the 13 companies on this page; the largest is Curis (CRIS) at $2.97M.
KPTI pages: Overview, Earnings, Forecast, Financials, Competitors